Genentech in $1.7bn immuno-oncology deal

California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Roche and Innovent unite in $2bn biospecifics deal

15 June 2020 Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.

Big Pharma

Genentech enters agreement to develop autoimmune therapies

21 May 2019 US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.

Americas

Bioverativ and Bicycle Therapeutics in $10m haemophilia deal

7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Genentech in $1.7bn immuno-oncology deal

More on this story

Editor's picks

Editor's picks

More features